Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Monday's Health Winners & Losers

Shares of cancer-drug maker Celgene (CELG) sank after research firm SG Cowen initiated coverage of the stock with a neutral rating.

While Cowen's biotech analyst Phil Nadeau says revenue from the company's Revlimid should reach $2.3 billion in 2010 from $331 million for all of 2006, the drug's success is already priced into the stock, which is "modestly overvalued," he believes. Nadeau says he would look for a pullback before building a position. Shares fell 3.4% to $44.39.

MicroIslet (MII) fell despite an announcement that the company's transplantation studies on diabetic primates reached a six-month milestone. After jumping early in the day, shares were lower by 9 cents, or 5%, to $1.70.

Shares of medical-aesthetics company Syneron (ELOS) were jumping 15.6% to $21.39 after the company reported earnings and reiterated its guidance. Syneron's quarterly revenue reached $27.5 million, up 37% from a year ago and was a record high. Overall, the company earned $8.9 million, or 32 cents a share, including stock-based compensation expenses.

Excluding charges, the company earned $11.3 million, or 41 cents a share, in the quarter, up 22% from last year. Analysts were expecting the company to earn 39 cents a share. The company said it was on track to meet its previously announced guidance, which in February called for revenue of between $113 million and $120 million for the full year.

Among other health care stocks on the move were pharmaceutical company NitroMed (NTMD), which was gaining 14.1% to $2.91, drug developer Taro Pharmaceutical Industries (TARO), up 7.7% to $12.81, biotech ICAgen (ICGN), higher by 7.1% to $1.20, and Spectrum Pharmaceuticals (SPPI), up 3.4% to $3.68.

Accentia Biopharmaceuticals (ABPI) was down 1.6% to $3.03, Ivax Diagnostics (IVD) fell 8.2% to $1.56, Oscient Pharmaceuticals (OSCI) was down 6% to $1.25, Nyer Medical Group (NYER) lost 9.7% to $2.80, Alpharma (ALO) was down 6.6% to $21.65, and Rigel Pharmaceuticals (RIGL) was losing 3.8% to $9.20.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,387.58 52.30 0.34%
NASDAQ 3,502.12 5.69 0.16%
S&P 500 1,669.16 2.87 0.17%
US 10 Yr 1.944% -0.021

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs